您的购物车当前为空
别名 NU 6300
NU6300是一种共价的CDK2抑制剂,具有不可逆和ATP竞争性的特点,IC50=0.16 μM,抑制Rb(retinoblastoma tumor suppressor protein)磷酸化,可用于研究真核细胞周期和转录相。NU6300还是一种GSDMD(Gasdermin D)抑制剂,能够阻止半胱氨酸-191的裂解和棕榈酰化,抑制NLRP3的早期步骤,可用于结肠炎和脓毒症。

NU6300是一种共价的CDK2抑制剂,具有不可逆和ATP竞争性的特点,IC50=0.16 μM,抑制Rb(retinoblastoma tumor suppressor protein)磷酸化,可用于研究真核细胞周期和转录相。NU6300还是一种GSDMD(Gasdermin D)抑制剂,能够阻止半胱氨酸-191的裂解和棕榈酰化,抑制NLRP3的早期步骤,可用于结肠炎和脓毒症。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,290 | 8-10周 | |
| 5 mg | ¥ 5,399 | In stock |
NU6300 相关产品
| 产品描述 | NU6300 is a covalent CDK2 inhibitor exhibiting irreversible and ATP-competitive properties with an IC50 of 0.16 μM. It inhibits Rb (retinoblastoma tumour suppressor protein) phosphorylation and is suitable for research into eukaryotic cell cycle and transcription-related studies. NU6300 also functions as a GSDMD (Gasdermin D) inhibitor, blocking cleavage and palmitoylation of cysteine-191 to suppress early NLRP3 activation pathways, making it applicable for colitis and sepsis research. |
| 靶点活性 | CDK2:0.16 μM |
| 体外活性 | NU6300对细胞焦亡表现出剂量依赖性挽救作用,在THP-1细胞和骨髓来源的巨噬细胞(BMDM)中的一半最大抑制浓度(IC50)值分别为0.89和0.93μM。[1] |
| 别名 | NU 6300 |
| 分子量 | 413.49 |
| 分子式 | C20H23N5O3S |
| CAS No. | 2070015-09-5 |
| Smiles | C=CS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1 |
| 密度 | 1.344 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 80 mg/mL (193.48 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.98 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容